COMMUNIQUÉS West-GlobeNewswire

Philips introduces SmartIQ to address the trade-off between image quality and radiation dose in coronary procedures
18/05/2026
May 18, 2026 Greater differentiation of clinical details through contrast-rich images with reduced background noise For coronary procedures, a new ultra-low dose protocol employs over 50% less X-ray radiation dose [1] [...]
Red Ribbon Recovery Indiana reports strong patient outcomes in first year of operation
18/05/2026
New Indiana rehab reports 88% sobriety at 30 days — and 70% at six months Greenwood, Indiana, May 18, 2026 (GLOBE NEWSWIRE) -- Red Ribbon Recovery Indiana, which marks its first year of operation this June, is releasing [...]
Arbor Biotechnologies Appoints Mathew Pletcher, Ph.D., as Chief Scientific Officer
18/05/2026
Gene therapy and rare disease leader with nearly two decades of drug development experience to focus on advancing the company’s next-generation gene editing pipeline CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- [...]
UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
18/05/2026
Data from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH demonstrated clinically meaningful improvement in multiple assessments of lung function, including improvement in 6MWD [...]
Arvinas Employees Give Back During Company-wide Impact Day
18/05/2026
NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that [...]
GMR Solutions Inc. Announces Ratings Upgrade and Debt Reduction
18/05/2026
Post-IPO rating improvement from S&P Global Ratings and Moody’s Ratings LEWISVILLE, Texas, May 18, 2026 (GLOBE NEWSWIRE) -- GMR Solutions Inc. (NYSE: GMRS) and its wholly owned subsidiary Global Medical Response, [...]
CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates
18/05/2026
Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies in second half of 2026, subject to financing Presented new analyses at AAN 2026 highlighting [...]
BrainsWay Announces Minority-Stake Investment in Hopemark Health
18/05/2026
Investment in provider servicing clinics in Illinois is latest in series of similar transactions by BrainsWay with leading North American mental health providers to raise awareness and expand access to transformative [...]
Zenflow Presents the BREEZE™ Pivotal Clinical Trial at the American Urological Association Annual Meeting
18/05/2026
Data Supported the FDA Approval of the Zenflow Spring® Implant and Delivery System for BPH Additional presented data highlights patient satisfaction & long-term safety SOUTH SAN FRANCISCO, Calif., May 18, 2026 ( [...]
Glass House Brands Announces the Filing of Prospectus Supplement for Previously Announced At-The-Market Distribution Program
18/05/2026
LONG BEACH, Calif. and TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“ Glass House ” or the “ Company “) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF) announced today that, [...]
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
18/05/2026
Completed successful FDA End-of-Phase 2 meeting, reaching alignment on the study parameters of RESTORE, a registrational study of NVG-291 in chronic tetraplegia, with site activation underway and study initiation on [...]
Nature Human Behaviour study finds SilverCloud® by Amwell® reduced prevalence of mental disorders over two years at scale
18/05/2026
BOSTON, May 18, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today highlighted results from an independently led, [...]
Kraig Biocraft Laboratories Announces Breakthrough Creation of Immortalized Silkworm Silk Gland Cell Line with Broad Biotechnology Applications
18/05/2026
ANN ARBOR, Mich., May 18, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced a biotechnology [...]
Byondis Establishes Scientific Advisory Board of Recognized Leaders in Oncology Research and ADC Development
18/05/2026
Global experts in antibody-drug conjugate (ADC) development, oncology clinical development and early-phase trial design, appointed to support advancement of Byondis’ differentiated ADC pipeline and a new generation of [...]
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
18/05/2026
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform Agreement provides for Parabilis to receive $125M from Regeneron, consisting of [...]
Vincentage Pharma Reports Positive Top-Line Results from Pivotal Phase 3 Trial of VCT220 in Obese or Overweight Chinese Adults
18/05/2026
CHENGDU, China, May 18, 2026 (GLOBE NEWSWIRE) -- Vincentage Pharma Co., Ltd. (the “Company”) today announced positive top-line results from the Company’s pivotal Phase 3 trial evaluating its internally discovered, [...]
Juniper Biosciences Appoints Renowned Radiopharmaceutical Expert Jason S. Lewis, Ph.D. as Chair of Newly Formed Scientific Advisory Board
18/05/2026
BRIDGEWATER, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- Juniper Biosciences, a cutting-edge radiopharmaceutical drug development company, today announced the launch of its Scientific Advisory Board (SAB) and the appointment [...]
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
18/05/2026
Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license Phase 1 initiation for CT-202 trial expected in third quarter of 2026 PHILADELPHIA, May 18, 2026 [...]
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update
18/05/2026
Key highlights from the first quarter of operations under the expanded management team include the following: Anticipated FDA decision on the Company's ANDA for Preservative-Free Ketamine in Q3 2026, with favorable [...]

Pages